Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · IEX Real-Time Price · USD
6.42
+0.11 (1.74%)
At close: Apr 26, 2024, 4:00 PM
6.45
+0.03 (0.47%)
After-hours: Apr 26, 2024, 7:57 PM EDT
Ardelyx Revenue
In the year 2023, Ardelyx had annual revenue of $124.46M with 138.61% growth. Revenue in the quarter ending December 31, 2023 was $34.36M, a -22.22% decrease year-over-year.
Revenue (ttm)
$124.46M
Revenue Growth
+138.61%
P/S Ratio
12.00
Revenue / Employee
$466,127
Employees
267
Market Cap
1.49B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
Dec 31, 2017 | 42.00M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
Dec 31, 2012 | 5.41M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Warby Parker | 669.77M |
U.S. Physical Therapy | 604.80M |
ADMA Biologics | 258.22M |
Dynavax Technologies | 232.28M |
LeMaitre Vascular | 193.48M |
Gyre Therapeutics | 113.45M |
Protagonist Therapeutics | 60.00M |
ARDX News
- 4 weeks ago - Ardelyx, Inc. Reports Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy - GlobeNewsWire
- 2 months ago - Ardelyx to Participate at the Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 - GlobeNewsWire
- 3 months ago - Ardelyx stock: Is ARDX a good buy after the 1,360% surge? - Invezz
- 3 months ago - Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities - GlobeNewsWire
- 4 months ago - Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 - GlobeNewsWire